Bioreactor Market by Material Type (Glass, Stainless Steel, and Single Use), by Usage (Lab-Scale-Production, Pilot-Scale Production, and Full-Scale Production), by End User (Pharmaceuticals and Biopharmaceuticals Manufacturers, Contract Research Organizations Academic & Research Institutes, and Others) – Global Outlook & Forecast 2022-2030
According to the deep-dive market assessment study conducted by Growth + Reports, the global bioreactor market was pegged at ~ US$ 2.56 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 16.0% from 2022 to 2030.
The increasing focus of biologics manufacturers on scaling-up biologics production technologies is expected to drive the global bioreactors market trends. Furthermore, the rising demand for personalized medicines and the surge in demand for single-use bioreactors, combined with an increase in the number of FDA-approved orphan drugs, has resulted in increased bio production, which is expected to provide significant opportunities for industry growth in the coming years. For instance, in 2019, Getinge (Applikon Biotechnology), a manufacturer of upstream bioprocess equipment, introduced the single use AppliFlex ST lab-scale bioreactor, which is a fully customized single use bioreactor that comes with a pre sterilized and "ready to go" system, saving time during cell culture setup.
An increase in R&D activities to develop effective novel medicines for cancer treatment is expected to drive the demand for bioreactors. The bioreactor market is expanding rapidly due to growing need to scale up pharmaceutical production. Increased R&D efforts in this category, as well as rising demand for bioreactors from biopharmaceutical companies are the prime reasons for market growth.
The unexpected outbreak of COVID-19 pandemic has increased the demand for reactors. As the need for effective treatment therapies and preventive vaccinations grows many pharmaceutical and biopharmaceutical companies increased their research and development initiatives and consequently production capabilities to meet the needs of a large patient population, boosting bioreactor sales throughout the epidemic. Hence, growing R&D and production activities for preventive vaccines and treatments around the world have increased the demand for clinical-stage bioreactors. For instance, in September 2020, ABEC supplied CSR bioreactors to Serum Institute of India Pvt. Ltd. (SIIPL) for the manufacture of the COVID-19 vaccine. As a result of increased adoption of bioreactors in several manufacturing facilities, the market will continue to grow significantly during the forecast period.
The adoption of single-use bioreactors (SUBs) and hybrid bioreactors, as well as the growth of bioreactors in pharmaceuticals, are also influencing the bioreactor market growth. Biopharmaceuticals are used in a variety of applications, ranging from biopharmaceutical production to tissue engineering applications such as cell expansion and the generation of 3D tissue constructs. Bioreactors are thus used to provide a controllable environment for any cells or cellular constructs that are incorporated into them in terms of pH, temperature, nutrient supply, and shear stress. Bioreactors have been used in a variety of industries and research settings, including the progression of in vitro models of 2D cultures and suspensions to 3D constructs that mimic the natural physiological state in situ. They have also been shown to be instrumental in developing important medicines in the treatment of autoimmune disorders, cancer, asthma, and organ rejection. Thus, the expansion of bioreactors in the pharmaceutical sector is a major factor driving market growth.
The rising cost of fermenters is expected to significantly limit revenue growth in the global bioreactors market. During the fermentation process in commercial or biopharmaceutical fermenters, the risk of contamination is relatively high. As a result, industrial fermenter manufacturers incorporate in-situ sterilization and cleaning systems into fermenters to avoid microbial infections during fermentation. This is expected to raise the cost of industrial fermenters, limiting the market's revenue growth.
North America is expected to witness the highest growth during the forecast period, owing to the region's increasing focus on product innovation, the presence of key players in advanced bioreactor manufacturing, and advancements in R&D in biomedical research. Additionally, the vast base of academic institutes, and R&D facilities support the market growth in North America.
Over the forecast period, Asia Pacific market is expected to grow at a consistent revenue CAGR. Rapid growth in the pharmaceutical industry in the region due to the availability of low-cost active pharmaceutical ingredients (API) and labor is expected to increase demand for bioreactors. Furthermore, governments are heavily investing in healthcare, CROs and R&D activities, contributing to the potential growth of the regional market. Regional market
participants are actively involved in R&D, which offers several innovative products, as well as collaboration between domestic and international biotechnology and pharmaceutical organizations for mass production, which is expected to drive Asia Pacific market demand.
The global market is characterized by a multitude of players who operate at both the regional and global levels. To gain a strong position in the market, key players are pursuing various strategies such as R&D investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures. Some of the key players operating the global bioreactor market are BBI-Biotech GmbH, Danaher Corporation, Bioengineering AG, Eppendorf AG, Getinge, Sartorius AG, Infors HT, Merck KgaA, Thermo Fisher Scientific, Inc., and Solaris Biotech Solutions.